These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 24458078

  • 1. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
    Macdougall IC, Strauss WE, McLaughlin J, Li Z, Dellanna F, Hertel J.
    Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
    [Abstract] [Full Text] [Related]

  • 2. Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.
    Macdougall IC, Strauss WE, Dahl NV, Bernard K, Li Z.
    Clin Nephrol; 2019 Apr; 91(4):237-245. PubMed ID: 30802204
    [Abstract] [Full Text] [Related]

  • 3. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
    Macdougall IC, Dahl NV, Bernard K, Li Z, Batycky A, Strauss WE.
    BMC Nephrol; 2017 Apr 03; 18(1):117. PubMed ID: 28372549
    [Abstract] [Full Text] [Related]

  • 4. A Phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy.
    Hetzel D, Strauss W, Bernard K, Li Z, Urboniene A, Allen LF.
    Am J Hematol; 2014 Jun 03; 89(6):646-50. PubMed ID: 24639149
    [Abstract] [Full Text] [Related]

  • 5. Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.
    Bielesz B, Lorenz M, Monteforte R, Prikoszovich T, Gabriel M, Wolzt M, Gleiss A, Hörl WH, Sunder-Plassmann G.
    Clin J Am Soc Nephrol; 2021 Oct 03; 16(10):1512-1521. PubMed ID: 34470831
    [Abstract] [Full Text] [Related]

  • 6. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
    Ziedan A, Bhandari S.
    Trials; 2019 Apr 04; 20(1):194. PubMed ID: 30947751
    [Abstract] [Full Text] [Related]

  • 7. Ferumoxytol: an intravenous iron, riskier than iron sucrose.
    Prescrire Int; 2013 Sep 04; 22(141):206. PubMed ID: 24171212
    [No Abstract] [Full Text] [Related]

  • 8. Intravenous iron monotherapy for the treatment of non-iron-deficiency anemia in cancer patients undergoing chemotherapy: a pilot study.
    Abdel-Razeq H, Abbasi S, Saadi I, Jaber R, Abdelelah H.
    Drug Des Devel Ther; 2013 Sep 04; 7():939-44. PubMed ID: 24039403
    [Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of ferumoxytol in hemodialysis patients at 3 dialysis chains in the United States over a 12-month period.
    Schiller B, Bhat P, Sharma A.
    Clin Ther; 2014 Jan 01; 36(1):70-83. PubMed ID: 24315802
    [Abstract] [Full Text] [Related]

  • 10. A randomized trial of intravenous and oral iron in chronic kidney disease.
    Agarwal R, Kusek JW, Pappas MK.
    Kidney Int; 2015 Oct 01; 88(4):905-14. PubMed ID: 26083656
    [Abstract] [Full Text] [Related]

  • 11. Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial.
    Onken JE, Bregman DB, Harrington RA, Morris D, Buerkert J, Hamerski D, Iftikhar H, Mangoo-Karim R, Martin ER, Martinez CO, Newman GE, Qunibi WY, Ross DL, Singh B, Smith MT, Butcher A, Koch TA, Goodnough LT.
    Nephrol Dial Transplant; 2014 Apr 01; 29(4):833-42. PubMed ID: 23963731
    [Abstract] [Full Text] [Related]

  • 12. Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients.
    Provenzano R, Schiller B, Rao M, Coyne D, Brenner L, Pereira BJ.
    Clin J Am Soc Nephrol; 2009 Feb 01; 4(2):386-93. PubMed ID: 19176796
    [Abstract] [Full Text] [Related]

  • 13. Ferumoxytol: a new era of iron deficiency anemia treatment for patients with chronic kidney disease.
    Kowalczyk M, Banach M, Rysz J.
    J Nephrol; 2011 Feb 01; 24(6):717-22. PubMed ID: 21956770
    [Abstract] [Full Text] [Related]

  • 14. Review of available intravenous iron preparations in hemodialysis.
    Palmer K, Cameron K, Battistella M.
    CANNT J; 2013 Feb 01; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract] [Full Text] [Related]

  • 15. Factors affecting response and tolerability to ferumoxytol in nondialysis chronic kidney disease patients.
    Fishbane S, Bolton WK, Winkelmayer WC, Strauss W, Li Z, Pereira BJ.
    Clin Nephrol; 2012 Sep 01; 78(3):181-8. PubMed ID: 22874106
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the safety and efficacy of 3 iron sucrose iron maintenance regimens in children, adolescents, and young adults with CKD: a randomized controlled trial.
    Goldstein SL, Morris D, Warady BA.
    Am J Kidney Dis; 2013 Apr 01; 61(4):588-97. PubMed ID: 23245582
    [Abstract] [Full Text] [Related]

  • 17. A randomized, open-label trial of iron isomaltoside 1000 (Monofer®) compared with iron sucrose (Venofer®) as maintenance therapy in haemodialysis patients.
    Bhandari S, Kalra PA, Kothari J, Ambühl PM, Christensen JH, Essaian AM, Thomsen LL, Macdougall IC, Coyne DW.
    Nephrol Dial Transplant; 2015 Sep 01; 30(9):1577-89. PubMed ID: 25925701
    [Abstract] [Full Text] [Related]

  • 18. FDA report: Ferumoxytol for intravenous iron therapy in adult patients with chronic kidney disease.
    Lu M, Cohen MH, Rieves D, Pazdur R.
    Am J Hematol; 2010 May 01; 85(5):315-9. PubMed ID: 20201089
    [Abstract] [Full Text] [Related]

  • 19. Ferumoxytol for treating iron deficiency anemia in CKD.
    Spinowitz BS, Kausz AT, Baptista J, Noble SD, Sothinathan R, Bernardo MV, Brenner L, Pereira BJ.
    J Am Soc Nephrol; 2008 Aug 01; 19(8):1599-605. PubMed ID: 18525001
    [Abstract] [Full Text] [Related]

  • 20. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
    Womack R, Berru F, Panwar B, Gutiérrez OM.
    Clin J Am Soc Nephrol; 2020 Sep 07; 15(9):1251-1258. PubMed ID: 32694162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.